Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open, Controlled, Parallel Group Study of Adding Linagliptin to Control Glycemic Variability and HbA1c in Peritoneal Dialysis Patients With Type 2 Diabetes(PDPD) With Premixed Insulin Therapy

NCT03320031 is registered in ClinicalTrials.gov with Yanbing Li as lead sponsor.

NCT NCT03320031
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03320031 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open, Controlled, Parallel Group Study of Adding Linagliptin to Control Glycemic Variability and HbA1c in Peritoneal Dialysis Patients With Type 2 Diabetes(PDPD) With Premixed Insulin Therapy
Lead sponsor
Yanbing Li
Phase
Phase 4
Overall status
Unknown status
Start date
June 3, 2017
Completion date
December 31, 2019
Enrollment
232 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

peritoneal dialysis, type 2 diabetes mellitus